logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Symeres Acquires Exemplify Biopharma, Further Strengthening Its Strategic Foothold In The Us

Oct 25, 2022•about 3 years ago

Acquiring Company

Symeres

Acquired Company

Exemplify BioPharma

NijmegenresearchBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth Care

Description

Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), today announces the acquisition of Exemplify BioPharma (or "Exemplify"), a US based CRO that provides integrated drug development services in Process & Analytical Chemistry and Formulation Development to pharmaceutical and biotech partners.

Company Information

Company

Symeres

Location

1013 Kerkenbos

Nijmegen, Gelderland, Netherlands

About

Symeres is a leading mid-sized transatlantic Contract Research Organization (CRO) specializing in drug discovery and development. With about 600 scientists across six European sites and two U.S. locations, Symeres delivers best-in-class solutions from early-stage hit finding to the production of early clinical drug substance APIs. Large enough to provide full capabilities yet small enough to offer personalized service, Symeres combines deep scientific expertise with creativity to accelerate breakthroughs for its partners.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed